Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer
Author: Muralidhar, V.
Catalano, P.
Reznor, G.
Mahal, B.
Choueiri, T.
Sweeney, C.
Martin, N.
Beard, C.
Chen, Y.
Nezolosky, M.
Hoffman, K.
Feng, F.
Trinh, Q.
Nguyen, P.
Citation: Journal of the National Comprehensive Cancer Network, 2016; 14(4):421-428
Publisher: Jones and Barlett Publishers
Issue Date: 2016
ISSN: 1540-1405
Statement of
Vinayak Muralidhar, Brandon Arvin Virgil Mahal, Gally Reznor, Toni K. Choueiri, Christopher Sweeney, Neil E. Martin, Peter F. Orio, Yu-Wei Chen, Michelle Daniel Nezolosky, Karen E. Hoffman, Felix Yi-Chung Feng, Quoc-Dien Trinh, Paul L. Nguyen
Abstract: The current NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer recommend long-term androgen deprivation therapy (ADT) for all men with high-risk prostate cancer treated with external-beam radiation therapy (EBRT). We determined whether the use of long-term ADT varied by the recently defined subcategories of high-risk disease (favorable, other, and very high) versus unfavorable intermediate-risk disease.We identified 5,524 patients with unfavorable-risk prostate cancer diagnosed from 2004 to 2007 and managed with EBRT using the SEER-Medicare linked database. Patients were stratified by risk group: unfavorable intermediate-risk, favorable high-risk (previously defined and validated as clinical stage T1c, Gleason score of 4 + 4 = 8, and prostate-specific antigen [PSA] level <10 ng/mL, or clinical stage T1c, Gleason score of 6, and PSA level >20 ng/mL), very-high-risk (clinical stage T3b-T4 or primary Gleason pattern 5), or other high risk (ie, neither favorable nor very high). We used multivariable competing risks regression to estimate the rates of long-term (≥2 years) ADT by group.Men with favorable high-risk prostate cancer were significantly less likely to receive long-term ADT than those with other high-risk disease (15.4% vs 24.6%, adjusted hazard ratio [AHR], 0.68; 95% CI, 0.60-0.76;P<.001), and similarly likely as those with unfavorable intermediate-risk disease (AHR, 1.10; 95% CI, 0.99-1.23;P=.087). Other high-risk disease was less likely to receive long-term ADT than very high-risk cancer (24.6% vs 30.8%; AHR, 0.83; 95% CI, 0.74-0.93;P=.002).Despite current guidelines, patients with EBRT-managed high-risk prostate cancer received significantly different rates of long-course ADT based on subclassification. Our results suggest that oncologists view these patients as a heterogeneous group with favorable high-risk cancer warranting less aggressive therapy than other high-risk or very high-risk disease.
Keywords: Androgen deprivation therapy; African-American men; cardiovascular-disease; radiation-therapy; trial; radiotherapy; suppression; mortality; duration
Rights: Copyright © 2016 by the National Comprehensive Cancer Network.
RMID: 0030048664
DOI: 10.6004/jnccn.2016.0048
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.